Côte d'Ivoire vs Iceland: Access to anti-retroviral drugs, female
Côte d'Ivoire
84.0%
in 2024
Iceland
86.0%
in 2024
Côte d'Ivoire rank
50th
Iceland rank
47th
Access to anti-retroviral drugs, female over time
- Côte d'Ivoire
- Iceland
How they compare
Iceland currently reports 86.0% against 84.0% in Côte d'Ivoire, a difference of 2.0%.
Across all 25 years both countries report, Iceland has been ahead every year.
Côte d'Ivoire ranks 50th and Iceland ranks 47th of 141 countries.
Iceland has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Côte d'Ivoire | Iceland | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 4.8% | 63.4% | 58.6% | Iceland |
| 2010s | 41.6% | 84.0% | 42.4% | Iceland |
| 2020s | 78.2% | 83.6% | 5.4% | Iceland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Côte d'Ivoire or Iceland?
- Iceland, at 86.0% against 84.0% in Côte d'Ivoire as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Côte d'Ivoire and Iceland?
- 2.0%, with Iceland ahead.
- How many years of comparable data are there for Côte d'Ivoire and Iceland?
- 25 years are reported by both, from 2000 to 2024.
- How do Côte d'Ivoire and Iceland rank globally for access to anti-retroviral drugs, female?
- Côte d'Ivoire ranks 50th and Iceland ranks 47th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.